Effects of Smoked Marijuana on Neuropathic Pain
Neuropathic Pain
About this trial
This is an interventional treatment trial for Neuropathic Pain focused on measuring cannabis, marijuana, neuropathy, antinociception, mood, cognition
Eligibility Criteria
Inclusion Criteria: Able to understand English Age greater than 18 and less than 70 VAS greater than 3/10 History of previous marijuana use (i.e., avoidance of marijuana naive subjects) Negative urine drug screening test Nerve Injury a.k.a. Complex Regional Pain Syndrome Type II OR Complex Regional Pain Syndrome Type I OR Neuropathic pain due to confirmed bilateral distal peripheral neuropathy associated with Diabetes I or II, focal nerve injury, postherpetic neuralgia, spinal cord injury with incomplete myelopathy, central pain following a stroke or focal brain lesion, or clinical definite multiple sclerosis of at least 3 months duration. Exclusion Criteria: Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied Unstable Type 1 or 2 diabetes defined as blood glucose more than 156 mg/dl For diabetic subjects maintained on insulin with a stable blood glucose more than 156 mg/dl, a hemoglobin A1C level of more than 0.11 (normal range, 0.048-0.067) History of traumatic brain injury History of schizophrenia or a past or current history of a serious psychiatric disorder that is currently not well controlled with medications Uncontrolled medical condition - coronary artery disease, hypertension, cerebrovascular disease, asthma, TB, COPD, opportunistic infection, malignancy requiring active treatment Active substance abuse (alcohol or injection drugs) Current use of marijuana (within 30 days of randomization) as determined by urine screening
Sites / Locations
- UC Davis Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
1
2
3
High dose cannabis (7.5% THC by weight)
Low dose cannabis (3.5% THC by weight)
Placebo cannabis